IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P Qureshi, Larry D Anderson · 2026
Read IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment by Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P Qureshi, Larry D Anderson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13575011.txt.
Description
Sridevi Rajeeve leads a 2026 real-world study of a cell therapy for multiple myeloma, a cancer of plasma cells in the bone marrow. The therapy, cilta-cel, uses a patient's own altered immune cells. It was first cleared for late-stage use and later moved into earlier lines of care.
Records covered 120 adults treated after one to three prior lines of therapy. Most received bridging treatment while the cells were prepared. Among those checked for response, 98 percent responded, and nearly all patients tested reached deep clearance of disease markers. At last follow-up, 94.2 percent stayed free of progression. Results held across bridging regimens, though follow-up was short at a median of 5.8 months.
Catalog record
| CREATOR | Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P Qureshi, Larry D Anderson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39499 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |